The antiphospholipid syndrome: Clinical characteristics, laboratory features and pathogenesis

Current Opinion in Infectious Diseases

Volumn 18, Issue 3, 2005, Pages 205-210

  De Groot, Philip G ^a   Derksen, Ronald H M W ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Rheumatology and Clinical Immunology ^*  (Netherlands)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Atherosclerosis; Lupus anticoagulants; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLOOD CLOTTING TIME; CHRONIC DISEASE; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; THROMBOSIS; VASCULAR DISEASE;

EID: 20044384361     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000168379.01272.53     Document Type: Review

References (37)

1. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic complications. J Thromb Haemostas 2003; 1:931-942.
2. de Groot PhG, Derksen RHWM. Antiphospholipid antibodies: Update on detection, pathophysiology and treatment. Curr Opin Haematol 2004; 11:165-169. Includes a discussion on the latest opinions on treatment of APS patients.
3. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
4. 2-glycoprotein I and prothrombin-dependent lupus anticoagulants. J Thromb Haemostas 2003; 1:740-747.
5. 2+ concentration are used to pick up a LAC caused by anti-β2GPI antibodies.
6. de Laat HB, Derksen RH, Urbanus RT, et al. beta2-Glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104:3598-3602. Showed the clinical importance of anti-β2GPI antibodies with LAC activity.
7. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827-1832.
8. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222-1226. Very interesting paper on the relation between complement activation and pregnancy morbidity.
9. Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies: when and how should they be measured? Thromb Res 2004; 114:527-531.
10. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102:2717-2723.
11. Reber G, Tincani A, Sanmarco M, et al. Proposals for the measurement of anti-beta2-glycoprotein I antibodies: standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2:1860-1862. A balanced proposal on how to perform an anti-β2GPI antibody ELISA.
12. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23:377-383.
13. Iverson GM, Reddel S, Victoria, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169:7097-7103.
14. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2005; 105:1540-1547. The relevant epitope for anti-β2GPI antibodies on β2GPI has been pinpointed on a positive cluster of amino acids on domain I of the protein. Correlations have been made between anti-β2GPI reactivity in an ELISA and LAC activity.
15. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349:2379-2380.
16. Ames PR, Margarita A, Sokoll KB, et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64:315-317.
17. Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25:198-203.
18. Toloza SM, Uribe AG, McGwin G Jr, et al. LUMINA Study Group, Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXIII: baseline predictors of vascular events. Arthritis Rheum 2004; 50:3947-3957.
19. Nicolo D, Monestier M. Antiphospholipid antibodies and atherosclerosis. Clin Immunol 2004; 112:183-189.
20. George J, Yacov N, Breitbart E, et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I. Cardiovasc Res 2004; 62:603-609.
21. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-2406.
22. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114:593-595. Another excellent study on the correlation of atherosclerosis and aPLs.
23. Horkko S, Miller E, Branch DW, et al. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci U S A 1997; 94:10356-10361.
24. Lopez D, Kobayasni K, Merrill JT, et al. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 2003; 10:203-211.
25. Liu Q, Kobayashi K, Furukawa J, et al. Omega-carboxyl variants of 7-keto-cholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 2002; 43:1486-1495.
26. Schlame M, Haller I, Sammaritano LR, Blanck TJ. Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies. Thromb Haemost 2001; 86:1475-1482.
27. Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103:2121-2126. Strong evidence that antibodies directed against tPA are of clinical relevance.
28. Yasuda S, Atsumi T, Ieko M, et al. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103:3766-3772. This article described elegantly how β92GPI can act as a negative regulator of fibrinolysis.
29. Guerin J, Sheng Y, Reddel S, et al. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein: elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002; 277:2644-2649.
30. Shi T, Iverson GM, Qi JC, et al. beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci U S A 2004; 101:3939-3944. Describes a possible role of β92GPI in the regulation of contact activation induced coagulation.
31. .].
32. Merten M, Motamedy S, Ramamurthy S, et al. Sulfatides: targets for anti-phospholipid antibodies. Circulation 2003; 108:2082-2087.
33. Rascni E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101:3495-3500.
34. Ma K, Simantov R, Zhang JC, et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275:15541-15548.
35. 2-glyco-protein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278:33831-33838.
36. Kuwana M, Matsuura E, Kobayashi K, et al. Binding of beta2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005; 105: 1552-1557. Very interesting study on how autoantibodies arise against β2GPI.
37. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79:42-45.